Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of LY900020 Formulations in Healthy Chinese Subjects
NCT04047940Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of orforglipron + metformin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve and Maximum Observed Drug Concentration. Started Nov 2019; status: completed.
02
Drugs
orforglipron + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04047940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047940.